Clinical Trials

July 3, 2013

Riociguat in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (EAS)

  • Official Title: An Open Label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
  • Study Sponsor: Bayer Healthcare Pharmaceuticals
  • Start Date: 03/2013
  • End Date: Until end of study
  • Design: Open label, single arm study
  • Age Range (years): from 18 to 80
  • Type of PH: CTEPH (Group 4)
  • Study Duration for Individual Patient: Until end of study
  • Contact: 1-888-842-2937 or
  • Listing on

FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2015 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.